Denileukin Diftitox
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Denileukin Diftitox: From Cutaneous T-Cell Lymphoma to Plasmacytoma
One-Sentence Summary
Denileukin diftitox (US brand LYMPHIR) is an IL-2/diphtheria toxin fusion protein approved for cutaneous T-cell lymphoma (CTCL). The TxGNN model predicts it may be effective for plasmacytoma, with a very high score (99.87%). However, there are currently 0 clinical trials and 0 publications supporting this specific prediction, so it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cutaneous T-cell lymphoma (CTCL) |
| Predicted New Indication | Plasmacytoma |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA761312) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not formally available in the database. From the supplied information, denileukin diftitox fuses interleukin-2 (IL-2) to diphtheria toxin. It targets cells that express the IL-2 receptor (CD25) and kills them. This is the basis of its use in CTCL, a lymphoid malignancy.
The link to plasmacytoma is weak on current data. Plasma cell neoplasms do not typically express CD25 as a defining feature, so the drug’s targeting logic may not carry over. This is an inference, not evidence from the supplied data. The high TxGNN score reflects a knowledge-graph pattern (a lymphoid or hematologic cancer drug matched to another blood cancer). It is not a demonstrated mechanistic or clinical connection.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| BLA 761312 | LYMPHIR (Citius Pharmaceuticals, Inc.) | Injection, powder, lyophilized, for solution |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (IL-2/diphtheria toxin fusion protein, an immunotoxin) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone (L5), with no trials or publications for plasmacytoma. The CD25-targeting mechanism also fits poorly with plasma cell neoplasms.
To proceed, the following is needed:
- Evidence that plasmacytoma cells express CD25 (or another route to drug sensitivity), plus preclinical data
- Full package insert warnings and contraindications
- Formal mechanism of action data
- A separate look at other predicted indications. Of these, only metastatic neoplasm (rank 4) has supporting studies. It has 13 registered trials and 7 publications, but the evidence is mixed and no Phase 3 RCT exists. Whether the drug actually depletes regulatory T cells is disputed (PMID 16224276 reports it did not), so this remains a research question rather than a ready candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.